Literature DB >> 23867349

OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort.

Guoyu Mu1, Hongjiang Wang, Zhengang Cai, Hong Ji.   

Abstract

AIM: to test the possible association between the polymorphism of Osteopontin (OPN) gene with the risk and the clinical features of papillary thyroid cancer (PTC).
METHODS: A total of 363 PTC patients and 413 healthy controls were enrolled. OPN expressions in tumor tissue were detected by immunohistochemistry. OPN gene polymorphisms, namely, -66T>G (rs28357094), -156G>GG (rs17524488), and -443C>T (rs11730582), were determined.
RESULTS: We observed that the PTC patients had significantly higher rates of -443TT genotypes than controls (P<0.001). The multivariate logistic regression analysis showed a significantly increased risk for PTC for the -443CC genotype compared with the -443TT genotype (adjusted OR= 4.312, 95%CI: 2.747 -6.987, adjusted P < 0.001). OPN protein was not expressed in normal thyroid tissues while tumor samples from PTC patients were shown to have high expressions of OPN. Also, we found that the high OPN expressions were significantly more prevalent in -443CC carriers than TT carriers (P <0.001). Both the CC carriers and OPN expression were closely associated with the cervical lymph node metastasis and angiolymphatic invasion of PTC.
CONCLUSION: This study provides evidence to support the connection between the OPN genetic polymorphism and tissue expression with risk as well as the invasiveness of PTC.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23867349     DOI: 10.1159/000350133

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Association of osteopontin polymorphism with cancer risk: a meta-analysis.

Authors:  Gang Yang; Xiaoxing Peng; Pengju Guo; Ge Yang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Association of OPN rs11730582 polymorphism with cancer risk: a meta-analysis.

Authors:  Lanlan He; Yong Wang
Journal:  Onco Targets Ther       Date:  2016-03-07       Impact factor: 4.147

4.  OPN gene polymorphisms, rs17524488 GG/G, rs11730582 T/C, and rs9138 C/A, and cancer risk in a Chinese population.

Authors:  Yuanyuan Mi; Kewei Ren; Feng Dai; Lijie Zhu; Ninghan Feng
Journal:  Sci Rep       Date:  2015-09-15       Impact factor: 4.379

5.  Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis.

Authors:  Yulan Liu; Hongbo Lei; Jixiang Zhang; Jun Wang; Kui Li; Weiguo Dong
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

6.  OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC.

Authors:  Yanzhang Hao; Jianwei Liu; Ping Wang; Feng Wang; Zeshun Yu; Mianli Li; Shaoshui Chen; Fangling Ning
Journal:  Int J Genomics       Date:  2014-08-05       Impact factor: 2.326

7.  Association between promoter polymorphisms of OPN gene and cancer risk: a meta-analysis.

Authors:  Jingwei Liu; Caiyun He; Quan Yuan; Zhenning Wang; Chengzhong Xing; Yuan Yuan
Journal:  Onco Targets Ther       Date:  2015-12-30       Impact factor: 4.147

Review 8.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.